Sen. Grassley’s Proposed Drug Safety Office Would Have Labeling Authority
This article was originally published in The Tan Sheet
Executive Summary
Sen. Charles Grassley (R-Iowa) will propose legislation creating an independent drug safety office at FDA that would have authority to alter drug labeling and possibly suspend direct-to-consumer advertising
You may also be interested in...
Health Chair Enzi Envisions Timely Crawford Confirmation
Senate Health Committee Chairman Michael Enzi (R-Wyo.) expects a vote on Acting FDA Commissioner Lester Crawford's nomination to the permanent post to proceed as scheduled on April 13
Crawford Must Answer “Tough Questions” During Confirmation – Grassley
Sen. Charles Grassley (R-Iowa) is noncommittal on the nomination of FDA Acting Commissioner Lester Crawford to fill the post on a permanent basis
Senate Hearings Probe FDA Authority On Drug Label Changes, Safety Trials
Giving FDA the authority to require changes to drug labeling could help the agency get drug safety information to the public more quickly, FDA Office of New Drugs Deputy Director Sandra Kweder told the Senate Health Committee March 1